Navigation Links
Heptares to Moderate Panel on Global Business Development at Upcoming Boston Biotech East/West CEO Conference
Date:1/8/2014

WELWYN GARDEN CITY, England and BOSTON, January 8, 2014 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that its President, Dan Grau, will moderate a panel discussion entitled "Global Entrepreneurs: Biotech Building Beyond Borders" (1:30-2:00pm Eastern time on 11 January) at the Boston Biotech East/West CEO Conference, which takes place at the Four Seasons Hotel, San Francisco, CA, USA on 11-12 January.

Mr Grau, Malcolm Weir (CEO), Fiona Marshall (CSO) and Barry Kenny (CBO) will attend the JPMorgan Healthcare conference, also in San Francisco, on 13-16 January.

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

StaR is a registered trademark in the EU and Japan.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
2. Heptares Achieves First Research Milestone in Research Collaboration with Cubist
3. Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
4. Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
5. Heptares to Present at the 6th Annual European Life Sciences CEO Forum (5-6 March)
6. Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)
7. Heptares and UK Medical Research Council Extend GPCR Collaboration
8. Turkish Diagnostic Imaging System Market Will Fluctuate, While Russian Market Will Grow Moderately Through 2022
9. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
10. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
11. Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists Top Unmet Need in Mild to Moderate Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SAO PAULO , March 23, 2017 ... accordance with article 157, paragraph 4 of Law 6,404/76 ... Commission (CVM), hereby informs its shareholders and the market ... jointly with its subsidiary Centro de Diagnosticos por Imagem ... acquisition of 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" ...
(Date:3/23/2017)... , March 23, 2017 Ascendis Pharma ... innovative TransCon technology to address significant unmet medical needs ... host a conference call and webcast on Monday, April ... Endocrine Society in Orlando, Florida , ... pipeline candidates (TransCon Growth Hormone, TransCon PTH and TransCon ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... 82% of adults are unaware of the dangers that ... brush their teeth the minimum two times a day that dentists recommend. The ramifications of ... million hours of school and adults missing 164 million hours of work each year due ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Accreditation from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive ... is granted to organizations that have excellent programs for the delivery and improvement ...
(Date:3/23/2017)... ... 23, 2017 , ... Michael Lanteri Agency, an insurance and ... area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as the ... cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones Canine ...
(Date:3/23/2017)... ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System ... AMN Healthcare: Susan Salka , 43rd President of the United States of America: ... My Life In and Out of the Ring: Sugar Ray Leonard , JD, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, a company known ... health and nutrition, announced its product Leyzene is now available for purchase on ... supplements that help people improve all aspects of their health so they can ...
Breaking Medicine News(10 mins):